Skip to main content
Top
Published in: Digestive Diseases and Sciences 12/2006

01-12-2006 | Letter to the Editor

Is the Time for Absorption and Oxidation of 13C-Octanoate Really Negligible in the Gastric Emptying Breath Test?

Authors: Masaki Sanaka, Takatsugu Yamamoto, Yasushi Kuyama

Published in: Digestive Diseases and Sciences | Issue 12/2006

Login to get access

Excerpt

To the Editor: Breath testing using 13C-labeled octanoate allows indirect assessment of gastric emptying by monitoring 13CO2 exhaled [1, 2]. 13C-Octanoate is absorbed only after it is emptied from the stomach, and is oxidized to 13CO2 in the liver. The methodological relevance of the breath test is based on the assumption that intestinal absorption and hepatic oxidation progress so rapidly as to be bypassed effectively [1]. No one has doubted the validity of the assumption, because pulmonary 13CO2 excretion attains its peak level 10 min after direct administration of 13C-octanoate into the duodenum [1]. However, the rapid peak of 13CO2 excretion does not necessarily exclude the possibility that the slow absorption of 13C-octanoate is ongoing long after the time of peak excretion.
Literature
1.
go back to reference Ghoos YF, Maes BD, Geypens BJ, Mys G, Hiele MI, Rutgeerts PJ, Vantrappen G (1993) Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test. Gastroenterology 104:1640–1647PubMed Ghoos YF, Maes BD, Geypens BJ, Mys G, Hiele MI, Rutgeerts PJ, Vantrappen G (1993) Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test. Gastroenterology 104:1640–1647PubMed
2.
go back to reference Perri F, Clemente R, Festa V, Quitadamo M, Niro G, Andriulli A (1998) 13C-Octanoic acid breath test: a reliable tool for measuring gastric emptying. Ital J Gastroenterol Hepatol 30:211–217PubMed Perri F, Clemente R, Festa V, Quitadamo M, Niro G, Andriulli A (1998) 13C-Octanoic acid breath test: a reliable tool for measuring gastric emptying. Ital J Gastroenterol Hepatol 30:211–217PubMed
3.
go back to reference Sanaka M, Yamamoto T, Kuyama Y (2005) Theoretical flaws in gastric emptying breath test: Why is it dubious? Dig Dis Sci 50:15–17CrossRefPubMed Sanaka M, Yamamoto T, Kuyama Y (2005) Theoretical flaws in gastric emptying breath test: Why is it dubious? Dig Dis Sci 50:15–17CrossRefPubMed
4.
go back to reference Rowland M, Tozer TN (1995) Clinical pharmacokinetics—concepts and applications. 3rd ed. Williams and Wilkins, Baltimore Rowland M, Tozer TN (1995) Clinical pharmacokinetics—concepts and applications. 3rd ed. Williams and Wilkins, Baltimore
5.
go back to reference Sanaka M, Yamamoto T, Ishii T, Kuyama Y (2004) The Wagner-Nelson method can generate an accurate gastric emptying flow curve from 13CO2 data obtained by a 13C-labeled substrate breath test. Digestion 69:71–78CrossRefPubMed Sanaka M, Yamamoto T, Ishii T, Kuyama Y (2004) The Wagner-Nelson method can generate an accurate gastric emptying flow curve from 13CO2 data obtained by a 13C-labeled substrate breath test. Digestion 69:71–78CrossRefPubMed
Metadata
Title
Is the Time for Absorption and Oxidation of 13C-Octanoate Really Negligible in the Gastric Emptying Breath Test?
Authors
Masaki Sanaka
Takatsugu Yamamoto
Yasushi Kuyama
Publication date
01-12-2006
Published in
Digestive Diseases and Sciences / Issue 12/2006
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-006-9392-x

Other articles of this Issue 12/2006

Digestive Diseases and Sciences 12/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine